New Risk • May 25
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr4.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 6.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (kr1.9m revenue, or US$209k). Market cap is less than US$10m (kr11.9m market cap, or US$1.28m). Reported Earnings • May 20
First quarter 2026 earnings released First quarter 2026 results: Revenue: kr306.0k (down 12% from 1Q 2025). Net loss: kr1.35m (loss widened 53% from 1Q 2025). Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Anders Hultman was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Feb 04
Polymer Factory's Dendritic Polymers Demonstrate Strong Antimicrobial Performance in Advanced Fiber Membranes Polymer Factory announced new research results demonstrating that fiber membranes incorporating the Company's proprietary dendritic polymers exhibit strong antimicrobial performance against both bacterial and viral strains. In the study, researchers successfully fabricated electrospun fiber membranes based on biodegradable and biocompatible poly(L-lactide-co-caprolactone) (PLCL), functionalized with positively and negatively charged dendritic polymers supplied by Polymer Factory. Morphological and physicochemical analyses confirmed the successful formation of multifunctional fibers using a scalable electrospinning process. The functionalized fibers demonstrated strong antibacterial performance, achieving greater than 99.9% efficacy against both gram-negative Escherichia coli and gram-positive Staphylococcus aureus. In addition, the membranes showed a significant antiviral effect, with more than 97% efficacy against an enveloped coronavirus strain (OC43). The effectiveness against other types of viruses requires further study. The results highlight the antimicrobial functionality of Polymer Factory's charged dendritic polymers and their compatibility with scalable fiber manufacturing techniques. The developed fiber membranes show potential to supplement existing filtration technologies and support the development of advanced filtration membranes and next-generation personal protective equipment (PPE), particularly for addressing environmental and biological pollution in indoor environments. Aankondiging • Oct 02
Polymer Factory Sweden AB Announces CEO Changes Polymer Factory Sweden AB announced that CEO Elin Mignérus and the Company's Board of Directors have mutually agreed to part ways. Elin Mignérus will step down from her position at the end of the year, effective December 30, 2025. Mats Wallnér, who has served as Acting CEO since January 1, 2025, will continue in this role until further notice. Aankondiging • Aug 29
Polymer Factory Sweden AB (publ) Grants Dendritic Nanogel (DNG) Patent in Multiple European Countries Polymer Factory Sweden AB (publ) announced that its patent application for the Company's dendritic nanogel (DNG) platform has been granted in several European countries. The DNG platform is an innovative nanocarrier system based on dendritic materials, designed to encapsulate, transport, and control the release of various cargos, including pharmaceuticals, peptides, and antibiotics. DNG offers a novel alternative to established drug delivery systems such as polymeric micelles and liposomes. The patent was filed on August 13, 2019, and will be valid for 20 years from the date of grant, ensuring market exclusivity during this period. This follows the Company's previously granted DNG patents in the United States and China in 2024. Aankondiging • Aug 18
Polymer Factory Receives SpheriCal Patent in Multiple European Countries Polymer Factory has been granted the SpheriCal patent in several European countries. The patent, valid for 20 years, is titled "Functionalized calibrants for spectrometry and chromatography" and was filed on May 29, 2018. The granted patent covers the following countries: United Kingdom, Austria, Belgium, Bulgaria, Germany, Denmark,stonia, Finland, France, Italy, Latvia, Luxembourg, Lithuania, Malta, the Netherlands, Portugal, Romania, Sweden, and Slovenia. Aankondiging • Aug 08
Polymer Factory Announces Breakthrough in Cancer Drug Delivery: Polymer-Based Nanocarriers Show Promise Against Aggressive Tumors Polymer Factory announced researchers have made a promising breakthrough in the fight against two of the most aggressive and treatment-resistant cancers: glioblastoma (GBM) and triple-negative breast cancer (TNBC). The study, conducted in collaboration with Polymer Factory, explored new ways to deliver cancer drugs more effectively using advanced polymer-based nanocarriers. Treat GBM and TNBC is notoriously difficult. Traditional chemotherapy struggles with issues such as poor drug solubility, toxicity, and, in the case of brain tumors, the blood-brain barrier - a natural defense that blocks many drugs from reaching the tumor. To tackle these challenges, the research team tested two innovative drug delivery systems: Polymeric micelles made from two commercially available systems; Dendritic nanogels (DNGs) based on Polymer Factory's proprietary bis-MPA dendritic nanotechnology. These nanocarriers were designed to encapsulate and transport common chemotherapy agents like docetaxel, carboplatin, and doxorubicin, increasing their stability and effectiveness. The results were encouraging: DNGs were especially effective at delivering water-soluble drugs, offering high loading capacity; Micelles improved solubility and uptake of water-insoluble drugs like docetaxel; Both systems showed strong tumor penetration and significantly reduced cancer cell growth in laboratory tests. The findings not only offer hope for future cancer therapies but also highlight the potential of polymer-based nanotechnology in personalized medicine. Aankondiging • Jun 03
Bruker Launches Qsee in Partnership with Polymer Factory Bruker launched the QSee quality control (QC) suite of software and reference materials for automated evaluation of instrument performance and long-term monitoring via cloud-based TwinScape software. In partnership with Polymer Factory Sweden AB, the leading manufacturer of stable polymer-based mass spectrometry instruments, the SpheriCal platform has been extended to include the new QSee™?8-mix for assessment of chromatographic and mass spectrometry performance. Results are archived for comparison across time using the TwinScape™? cloud-based solution already available for proteomics. Reported Earnings • Nov 10
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr1.06m (up 151% from 3Q 2023). Net loss: kr931.0k (loss widened 31% from 3Q 2023). Aankondiging • Nov 07
Polymer Factory Sweden AB Announces CEO Changes, Effective 1 January 2025 Mats Wallnér, board member of Polymer Factory Sweden AB (publ),will take over as acting CEO on 1 January 2025, when Elin Mignérus will take parental leave. Starting January 1, 2025, Mats Wallnér will take over as acting CEO, as current CEO Elin Mignérus takes parental leave. Sharing management responsibility, Michael Malkoch will also take on increased operational duties within his role as CTO for the Company. Both Mats and Michael have previously held the CEO position at Polymer Factory, and being part of the founding team, they have great knowledge about the Company, technology, and business. Elin Mignérus, who took over as CEO in April 2021, plans to be on parental leave during 2025. Aankondiging • Jul 03
Polymer Factory Sweden AB Announces That Patent Application for the Company's Dendritic Nanogel Platform Has Been Granted Polymer Factory Sweden AB (publ) announced that the patent application for the company's dendritic nanogel platform has been granted and issued as of July 2, 2024, by the US Patent and Trademark Office, USPTO. The DNG platform is an innovative nanocarrier platform based on dendritic materials, with the potential to encapsulate, transport, and control the release of cargo (e.g., pharmaceuticals, peptides, and antibiotics). DNG is Polymer Factory's alternative carrier to already established liposome carriers. The filing date for the patent application is August 13, 2019, and it is granted for 20 years from the validity date, which provides market exclusivity during this period. Polymer Factory has filed corresponding patent applications in other geographies. Aankondiging • Jun 06
Polymer Factory Sweden AB Releases Spherical® Calibrants for Im-Ms Polymer Factory Sweden AB expanding the range of applications for its calibration technology SpheriCal®, the Company has commercially released calibrants for Ion Mobility Mass Spectrometry (IM-MS). The new technology was launched during the ongoing 72nd ASMS Conference on Mass Spectrometry and Allied Topics (ASMS) in Anaheim, USA, where Polymer Factory is exhibiting. Earlier this year, the Company announced the publication of a scientific article where scientists performed a proof-of-concept and suitability study on the use of compounds from Polymer Factory's SpheriCal® platform to tune and calibrate IM-MS devices. The article showed very promising results, and the Company has now translated these results into commercial products. During 2023, Polymer Factory engaged collaborators for evaluations within several new calibration areas, where IM-MS was represented. Initial results of the IM-MS development were presented by Polymer Factory's Product Manager at ASMS in June 2023, which gained much attention. Reported Earnings • May 10
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr696.0k (up 13% from 1Q 2023). Net loss: kr1.25m (loss narrowed 28% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Aankondiging • May 08
Polymer Factory Sweden AB, Annual General Meeting, Jun 05, 2024 Polymer Factory Sweden AB, Annual General Meeting, Jun 05, 2024, at 13:00 Central European Standard Time. Location: Teknikringen 48 1 tr Stockholm Sweden Agenda: To consider presentation of the annual report and the auditor's report Resolution in respect of adoption of the profit and loss statement and the balance sheet; to consider the company's profits or losses according to the adopted balance sheet; to consider the members of the Board of Directors' and the CEO's discharge from liability; to consider determination of the fees payable to the members of the Board of Directors and the auditor; to consider election of members of the Board of Directors and auditor; to consider nomination committee; to consider resolution on authorization for the Board of Directors to resolve on issues of shares, convertibles and/or warrants; and to consider other matters. Aankondiging • Apr 09
Polymer Factory Sweden AB to Report Q1, 2024 Results on May 08, 2024 Polymer Factory Sweden AB announced that they will report Q1, 2024 results on May 08, 2024 Reported Earnings • Feb 18
Full year 2023 earnings released: kr0.45 loss per share (vs kr0.42 loss in FY 2022) Full year 2023 results: kr0.45 loss per share (further deteriorated from kr0.42 loss in FY 2022). Revenue: kr2.82m (down 3.0% from FY 2022). Net loss: kr4.83m (loss widened 68% from FY 2022). Aankondiging • Jan 18
Polymer Factory Sweden AB to Report Fiscal Year 2023 Results on Feb 16, 2024 Polymer Factory Sweden AB announced that they will report fiscal year 2023 results on Feb 16, 2024 Aankondiging • Dec 21
Polymer Factory Sweden AB Releases SpheriCal®? Facilitants for ESI-MS Polymer Factory Sweden AB announced that Fulfilling the Company's goal of expanding the range of applications for its calibration technology SpheriCal®?, the Company has now commercially released calibrants for Electrospray Ionization Mass Spectrometry (ESI-MS). The concept of this new technology was introduced to the market during the 71st ASMS Conference on Mass Spectrometry and Allied Topics (ASMS) this summer and prototypes were released for beta testing earlier this fall. Currently, the Company has calibrants for MALDI-ToF MS commercially available, whereas the goal of the expansion of the SpheriCal®? platform is to increase the target group and with that the market potential. It is estimated that the market size and number of instruments is many times higher for ESI than for MALDI- ToF. During 2023, Polymer Factory has engaged collaborators for evaluations within several new calibration areas, such as Ion Mobility Spectrometry (IMS) and high molecular weight MALDI, the latter which the Company released for beta testing in August. The results of the IMS development were presented by Polymer Factory's Product Manager at ASMS in June 2023, which got a lot of attention and will be published in the scientific literature soon. Aankondiging • Oct 12
Polymer Factory Sweden AB to Report Q3, 2023 Results on Nov 10, 2023 Polymer Factory Sweden AB announced that they will report Q3, 2023 results on Nov 10, 2023 Reported Earnings • Aug 18
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr674.0k (up 211% from 2Q 2022). Net loss: kr1.07m (loss narrowed 28% from 2Q 2022). Aankondiging • Jul 18
Polymer Factory Sweden AB to Report Q2, 2023 Results on Aug 16, 2023 Polymer Factory Sweden AB announced that they will report Q2, 2023 results on Aug 16, 2023 Board Change • Jul 06
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Board Member Leif Gynnerstedt was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • May 31
Polymer Factory Sweden AB Trademark Spherical Is Registered in South Korea Polymer Factory has received news that the trademark SpheriCal is granted approval in South Korea as of May 19, 2023. As a step to strengthen the products' image and recognition, Polymer Factory has registered the trademark SpheriCal in several different geographies. The Company has now received the Statement of Grant from the Korean Intellectual Property Office (KIPO) for the trademark in the South Korea. Working with trademarks is a way for the Company to strengthen the products' image, The Company has now received the registration certificate from KIPO for the trademark in South Korea. Earlier in 2023, the trademark has been approved in the United States. Reported Earnings • Feb 12
Full year 2022 earnings released: kr0.42 loss per share (vs kr0.49 loss in FY 2021) Full year 2022 results: kr0.42 loss per share (improved from kr0.49 loss in FY 2021). Revenue: kr2.93m (up 14% from FY 2021). Net loss: kr2.87m (loss narrowed 15% from FY 2021). Aankondiging • Jan 12
Polymer Factory Sweden AB to Report Fiscal Year 2022 Results on Feb 10, 2023 Polymer Factory Sweden AB announced that they will report fiscal year 2022 results on Feb 10, 2023 Aankondiging • Dec 21
Polymer Factory Sweden AB Receives EDF Grant for Polymer Development Work Polymer Factory Sweden AB (publ) has been approved for a grant of €455k from the European Defence Fund (EDF) for participation in the project Nano-SHIELD. The Company will contribute with the development of dendritic polymers for use in products protecting against chemical, biological, radiation, and nuclear (CBRN) threats. The project spans over three years, starting in early 2023. The project Nano-SHIELD focuses on development of products that will have properties for elimination of bacteria, viruses (biological protection), degradation of chemicals from the air, and attenuation of radiation. The aim is for the systems to be in standard products, such as advanced facemasks, air filters, and coveralls for emergency use in standard emergency toolboxes. Polymer Factory will work on the development of dendritic polymers and other highly functional polymers for selective absorption and neutralization of toxic molecules (i.e., chemical weapons) and biological entities (i.e., biological weapons). The grant from the EDF focuses on research on innovative and future-oriented defence solutions, and Polymer Factory is part of a pan-European consortium consisting of eight participants stemming from industry (SMEs), academia and research institutes. The project spans over three years and is planned to start in early 2023. The grant covers 100% of the costs for the project and will be paid in three stages over the three-year project period. Aankondiging • Dec 07
Polymer Factory Sweden AB Launches New Product Platform: Dendritic Nanogels Polymer Factory Sweden AB announced the launch of the new dendritic platform Dendritic Nanogels (DNG). Through the launch of this platform, the Company fulfills an operational objective set out for 2022. On December 1st, Polymer Factory launched the company's latest dendritic platform, DNG. This is a nanocarrier platform with the potential use as delivery vehicles of pharmaceuticals, peptides, antibiotics etc. It is a novel platform of crosslinked nanoparticles, with features such as water solubility, biocompatibility, and degradability. The DNGs can be programmed to embed functionality and thereby allow them to act as nanoscopic delivery system of therapeutics, fragrances, peptides, and other organic molecules. The DNG technology is envisioned to be desired by different industries, particularly for therapeutic, biomedical and industrial use. Polymer Factory has pending patents protecting the novel DNG technology. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Board Member Leif Gynnerstedt was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • May 12
Polymer Factory Sweden AB, Annual General Meeting, Jun 08, 2022 Polymer Factory Sweden AB, Annual General Meeting, Jun 08, 2022. Agenda: To consider election of chairperson and secretary of the meeting; to consider preparation and approval of the voting list; to consider approval of the agenda; to consider election of one or two persons who shall approve the minutes of the meeting; to consider annual report and the auditor's report; to consider adoption of the profit and loss statement and the balance sheet; to consider company's profits or losses according to the adopted balance sheet; to consider Board of Directors' and the CEO's discharge from liability; to determination of the fees payable to the members of the Board of Directors and the auditor;to consider election of members of the Board of Directors and auditor; to consider nomination committee; to consider authorization for the Board of Directors to resolve on new share issues. Reported Earnings • May 11
First quarter 2022 earnings released First quarter 2022 results: Revenue: kr454.0k (down 42% from 1Q 2021). Net loss: kr1.05m (loss widened 55% from 1Q 2021). Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Board Member Leif Gynnerstedt was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: kr0.49 loss per share. Revenue: kr2.57m (up 86% from FY 2020). Net loss: kr3.38m (loss widened kr3.09m from FY 2020). Revenue was in line with analyst estimates. Aankondiging • Dec 23
Polymer Factory Sweden AB Launches New Product Platform: BowtieD® Polymer Factory Sweden AB announced the launch of the new dendritic platform BowtieD®. Through the launch of these next generation dendritic products, the Company already reaches an operational objective set out for 2022. BowtieD® is a platform consisting of bifunctional dendritic materials, meaning they can carry more than one functional group at its surface, through a bowtie structure. The materials are highly sophisticated and are built on strong scientific evidence. By launching BowtieD®, Polymer Factory becomes the first-in-world commercial provider of bifunctional dendrimers. The BowtieD® platform will primarily target the big pharma, biotech, diagnostic and medtech markets. In 2021, prior to the official launch of the platform, the Company has already completed a customized bifunctional dendrimer for a global biotech company. Reported Earnings • Nov 27
Third quarter 2021 earnings: Revenues in line with analyst expectations Third quarter 2021 results: Revenue: kr377.0k (flat on 3Q 2020). Net loss: kr933.0k (flat on 3Q 2020). Revenue was in line with analyst estimates. 